BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Vinke P, Wesselink E, van Orten-Luiten W, van Norren K. The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses. Int J Mol Sci 2020;21:E323. [PMID: 31947724 DOI: 10.3390/ijms21010323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lanas A. Proton Pump Inhibitor (PPI) co-therapy and gastrointestinal bleeding with antithrombotic drugs: a step forward but not enough. Eur J Intern Med 2021;85:23-4. [PMID: 33487506 DOI: 10.1016/j.ejim.2021.01.014] [Reference Citation Analysis]
3 Lai SW, Liao KF. Association Between Proton Pump Inhibitors Use and Dementia Risk. Am J Gastroenterol 2020;115:631. [PMID: 32141914 DOI: 10.14309/ajg.0000000000000576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Garegnani L, Escobar Liquitay CM, Puga-tejada M, Franco JV; Cochrane Gut Group. Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014585] [Reference Citation Analysis]
5 Rosenberg V, Tzadok R, Chodick G, Kariv R. Proton pump inhibitors long term use-trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiol Drug Saf 2021;30:1576-87. [PMID: 34453456 DOI: 10.1002/pds.5352] [Reference Citation Analysis]
6 Patti MG, Schlottmann F, Herbella FA. The Treatment of Esophageal Achalasia: At the Intersection Between Innovation and Patient's Care. J Laparoendosc Adv Surg Tech A 2020;30:233-5. [PMID: 31895620 DOI: 10.1089/lap.2019.0718] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cartee NMP, Wang MM. Binding of omeprazole to protein targets identified by monoclonal antibodies. PLoS One 2020;15:e0239464. [PMID: 32946534 DOI: 10.1371/journal.pone.0239464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Liu L, Yu Y, Fan Q, Wu Z, Li X, Luo H. Impact of proton pump inhibitor management committee's multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments. BMC Health Serv Res 2022;22:417. [PMID: 35351121 DOI: 10.1186/s12913-022-07820-x] [Reference Citation Analysis]
10 Bai Z, Ding N, Ge J, Wang Y, Wang L, Wu N, Wei Q, Xu S, Liu X, Zhou G. Esomeprazole overcomes paclitaxel-resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells. Cell Biol Int 2021;45:177-87. [PMID: 33049093 DOI: 10.1002/cbin.11481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Phillips ME, Hopper AD, Leeds JS, Roberts KJ, McGeeney L, Duggan SN, Kumar R. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol 2021;8:e000643. [PMID: 34140324 DOI: 10.1136/bmjgast-2021-000643] [Reference Citation Analysis]
12 Chen C, Liu H, Duan R, Wang F, Duan L. The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients. J Gastroenterol Hepatol 2021;36:2131-40. [PMID: 33586808 DOI: 10.1111/jgh.15432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Fuentes-Valenzuela E, Díez Redondo P, Tejedor-Tejada J, Nájera-Muñoz R, Sánchez-Delgado L, Maroto-Martín C. [Proton-pump inhibitors treatment. Does your patient really need it?]. Semergen 2021:S1138-3593(21)00266-5. [PMID: 34728148 DOI: 10.1016/j.semerg.2021.08.002] [Reference Citation Analysis]
14 Yi KH, Tan XR. Advances in prevention and treatment of digestive tract damage induced by antithrombotic therapy with traditional Chinese and Western medicine. Shijie Huaren Xiaohua Zazhi 2021; 29(19): 1089-1095 [DOI: 10.11569/wcjd.v29.i19.1089] [Reference Citation Analysis]
15 Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, Lee YY, Nair AB, Antony PT, Ford AC, Chaiyakunapruk N. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol 2021. [PMID: 34622475 DOI: 10.1111/bcp.15103] [Reference Citation Analysis]
16 Ben-Eltriki M, Green CJ, Maclure M, Musini V, Bassett KL, Wright JM. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect 2020;8:e00651. [PMID: 32996701 DOI: 10.1002/prp2.651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
17 Stenger Moura FC, Cechinel-Filho V, Greco FA, Venzon L, Meurer MC, França TCDS, Longo B, Somensi LB, Mariano LNB, Cruz AB, Macchiarulo A, Schoubben A, Ricci M, Belle Bresolin TM, da Silva LM. Taxifolin and gastro-adhesive microparticles containing taxifolin promotes gastric healing in vivo, inhibits Helicobacter pylori in vitro and proton pump reversibly in silico. Chem Biol Interact 2021;339:109445. [PMID: 33741339 DOI: 10.1016/j.cbi.2021.109445] [Reference Citation Analysis]
18 Verhasselt M, Rodriguez A, Dequanter D, Lechien JR. Chronic Course, Weaning, and Awareness of Patients With Reflux Toward Proton Pump Inhibitor Therapy. J Voice 2021:S0892-1997(21)00098-9. [PMID: 33795183 DOI: 10.1016/j.jvoice.2021.03.002] [Reference Citation Analysis]
19 Haskins IN, Lombardi ME, Overby DW, Farrell TM. The Endoscopic Management of Achalasia: Less May Lead to More. Am Surg 2021;:3134820984875. [PMID: 33460341 DOI: 10.1177/0003134820984875] [Reference Citation Analysis]
20 Calvo LLJ, García Cámara P, Llorente Barrio M, Sierra Gabarda O, Monzón Baez R, Arbonés Mainar JM, Alcedo González J, Bernal Monterde V. Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project. Eur J Clin Pharmacol 2021. [PMID: 34269841 DOI: 10.1007/s00228-021-03186-x] [Reference Citation Analysis]
21 Dipasquale V, Cicala G, Laganà F, Cutroneo P, Felicetti P, Potenza S, Trimarchi G, Spina E, Romano C. Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data. Expert Opin Drug Saf 2021;:1-6. [PMID: 34494498 DOI: 10.1080/14740338.2021.1978975] [Reference Citation Analysis]
22 Domper Arnal MJ, García Mateo S, Hermoso-Durán S, Abad D, Carrera-Lasfuentes P, Velazquez-Campoy A, Abian Franco O, Lanas A. False-positive fecal immunochemical test results in colorectal cancer screening and gastrointestinal drug use. Int J Colorectal Dis 2021;36:1861-9. [PMID: 33982138 DOI: 10.1007/s00384-021-03947-1] [Reference Citation Analysis]
23 Liu Y, Cao Z, Dai Y, Zeng L, Zhang Y, Fan H, Duan C, Tan N, He P. Association of Proton Pump Inhibitor and Infection and Major Adverse Clinical Events in Patients With ST-Elevation Myocardial Infarction: A Propensity Score Matching Analysis. Front Med 2022;9:882341. [DOI: 10.3389/fmed.2022.882341] [Reference Citation Analysis]
24 Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021;22:219-27. [PMID: 32893683 DOI: 10.1080/14656566.2020.1817385] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Saiz Ladera GM, Pejenaute Labari ME, García Pascual JN. [Updating in prescription of proton pump inhibitors. What to do and what not to do]. Semergen 2021;47:267-79. [PMID: 33223372 DOI: 10.1016/j.semerg.2020.09.011] [Reference Citation Analysis]